Opioid-use disorder (OUD) has become a national crisis, killing over 100 Americans daily and costing 78 billion dollars annually. The current therapy for opioid abuse has limited success with significant side effects, illicit use, and high attrition rates. However, research has demonstrated that immunopharmacotherapy a new treatment for opioid addiction in the pre-clinical phase, elicits an immune response which lacks abuse potential and decreases related mortality. Compared to current treatments, immunopharmacotherapy against a targeted opioid could offer suppression of addiction liability and overdose potential over an extended period of time without placing excessive compliance demands and adverse effects on the person.